Isaac Thangasamy

Dr. Isaac Thangasamy


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2014 in European Urology
Verified
Journal Article
Closed access
ITIsaac Thangasamy
Isaac Thangasamy
MLMichael Leveridge
Michael Leveridge
BDBenjamin J. Davies
Benjamin J. Davies
AFAntonio Finelli
Antonio Finelli
BSBrian Stork
Brian Stork
Henry WooHenry Woo
Henry Woo

1 March 2020 in European Urology
Verified
Journal Article
Closed access
NSNiranjan J. Sathianathen
Niranjan J. Sathianathen
SKSamantha Koschel
Samantha Koschel
ITIsaac Thangasamy
Isaac Thangasamy
JTJiasian Teh
Jiasian Teh
OAOmar Alghazo
Omar Alghazo
DMDeclan G. Murphy
Declan G. Murphy


1 June 2021 in Prostate International
Verified
Journal Article
Open access
TKTimothy Nathan Kwan
Timothy Nathan Kwan
SSSandra Spremo
Sandra Spremo
ATAmy Y.M. Teh
Amy Y.M. Teh
DMDavid McHarg
David McHarg
ITIsaac Thangasamy
Isaac Thangasamy
Henry WooHenry Woo
Henry Woo
We aimed to evaluate the utility of prostate-specific membrane antigen (PSMA) PET/CT for the detection of local disease within the prostate. This is a retrospective review of a single-center experience evaluating intraprostatic detection rates compared with final histopathology in a radical prostatectomy (RP) population. Seventy-two patients had PSMA PET/CT scan performed as part of their primary staging. Intraprostatic PSMA PET/CT avidity was assessed. PSMA PET/CT uptake was retrospectively correlated with patient characteristics including final histopathology, MRI Prostate Imaging Reporting and Data System (PI-RADS) score, clinical tumor stage, prostate-specific antigen (PSA) level, and patient age. The sensitivity of PSMA PET/CT for the detection of RP-confirmed prostate cancer was 81.2%. Much higher sensitivity was found within certain subpopulations. The patient characteristics that most strongly correlated with focal intraprostatic PSMA PET/CT uptake were patient age (Kendall's tau coefficient τb = 0.24, p < 0.05) and clinical T stage (τb = 0.21, p < 0.05). The International Society of Urological Pathology (ISUP) grade group from final RP was predicted by standardized uptake value (SUVmax) and to a lesser extent PSA and the maximal dimension of PET-avid lesions. SUVmax monotonically increased with ISUP grade group. If SUVmax was above 10 g/mL, the final RP histopathology had a relative risk of 2.3 (95% CI 1.3–4.1) of being ISUP grade group 5. This trial provides early evidence that PSMA PET/CT assists in the grading of prostate cancer and suggests that the imaging modality is particularly accurate in subpopulations including the elderly and those with palpable disease.

6 May 2021 in BJUI Compass
Verified
Journal Article
Open access
PDF file
TPTrent A. Pattenden
Trent A. Pattenden
RRRachael A. Raleigh
Rachael A. Raleigh
EPElle R. Pattenden
Elle R. Pattenden
ITIsaac Thangasamy
Isaac Thangasamy
Objectives: To investigate the quality and readability of online patient information on treatment for erectile dysfunction using a Google search.Materials and methods: The results of a Google search for “erectile dysfunction treatment” were reviewed. Webpages that contained written information on erectile dysfunction except those containing scientific publications and paywall protected webpages were included in further analysis. Typographic and treatment information were recorded. Readability was assessed using the Fleisch‐Kincaid grade level, the Gunning‐Fog index, the Coleman‐Liau index, and Simple Measure of Gobbledygook. Website quality was assessed using the DISCERN instrument, Journal of the American Medical Association (JAMA) benchmark criteria, and presence of Health on the net (HON) code certification. Website typography, discussed treatment types, readability scores, and quality measures were reported. Parametric and nonparametric statistical tests were used to compare the data as appropriate dependent on the normality of data.Results: Eighty‐one webpages were included. Urologists and hospitals were the most common producers with 15 (18%) each. Seventy‐four (91%) webpages contained specific information on treatment for erectile dysfunction and 15 (19%) contained advertisements. Seventeen (21%) webpages were HON code certified. The median DISCERN score was 35 (IQR 26.5‐44) out of 80. The mean combined readability score was 12.32 (SD 1.91). The median JAMA benchmark score was 1 (IQR 1‐2) out of 4. Google rank had a small negative correlation with DISCERN score (τ = −0.16, P = .036). HON code certified webpages had higher DISCERN scores (median of 44 [IQR 35‐58.5] vs 32.5 [IQR 25.25‐42.25], U = 832, Z = 6561, P < .001). A linear regression was used to predict DISCERN score based on meeting each JAMA benchmark criterion (F(2, 78) = 22.7, P < .001) R2 = 0.368, P < .001. Within this model the effects of meeting attribution (β = 11.09) and currency (β = 8.79) criterion were significant.Conclusions: The quality of online information on treatment for erectile dysfunction is generally poor. However, easy to identify markers of quality like HON code certification, or meeting JAMA benchmark criterion for attribution and currency may help patients to navigate to better quality online information on treatment for erectile dysfunction. Webpages are written at senior high school level, above any recommendations for patient medical information. Health professionals should use validated instruments to assess the quality of online information on treatment for erectile dysfunction prior to publication to improve their utility for patients.